Premium
This is an archive article published on January 12, 2012

StanChart upgrades Cipla to ‘outperform’

The bank said the depreciation of the rupee will also benefit the drugmaker.

Standard Chartered has upgraded Cipla to ‘outperform’ from ‘in-line’ and raised its stock target price to 400 rupees from 315 rupees on potential upside margins led by operating leverage benefits,improved products mix and higher contribution from developed markets.

The bank said the depreciation of the rupee will also benefit the drugmaker.

It positioned the stock for a valuation re-rating given lower earnings volatility,healthy balance sheet,potential for improved ratios and a reasonable risk-reward ratio,Standard Chartered added in a note on Wednesday.

At 11:12 a.m,shares of Cipla were up 1.01 per cent at 344 rupees.

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement